全文获取类型
收费全文 | 116篇 |
免费 | 9篇 |
国内免费 | 1篇 |
出版年
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2015年 | 1篇 |
2014年 | 10篇 |
2013年 | 3篇 |
2012年 | 5篇 |
2011年 | 8篇 |
2010年 | 6篇 |
2009年 | 2篇 |
2008年 | 4篇 |
2007年 | 2篇 |
2006年 | 6篇 |
2005年 | 3篇 |
2004年 | 3篇 |
2003年 | 6篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 9篇 |
1996年 | 3篇 |
1995年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1977年 | 1篇 |
1976年 | 4篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
1966年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有126条查询结果,搜索用时 15 毫秒
121.
Kerstin Brinkmann Paul Waring Stefan P Glaser Verena Wimmer Denny L Cottle Ming Shen Tham Duong Nhu Lachlan Whitehead Alex RD Delbridge Guillaume Lessene Ian M Smyth Marco J Herold Gemma L Kelly Stephanie Grabow Andreas Strasser 《The EMBO journal》2020,39(24)
Studies of gene‐targeted mice identified the roles of the different pro‐survival BCL‐2 proteins during embryogenesis. However, little is known about the role(s) of these proteins in adults in response to cytotoxic stresses, such as treatment with anti‐cancer agents. We investigated the role of BCL‐XL in adult mice using a strategy where prior bone marrow transplantation allowed for loss of BCL‐XL exclusively in non‐hematopoietic tissues to prevent anemia caused by BCL‐XL deficiency in erythroid cells. Unexpectedly, the combination of total body γ‐irradiation (TBI) and genetic loss of Bcl‐x caused secondary anemia resulting from chronic renal failure due to apoptosis of renal tubular epithelium with secondary obstructive nephropathy. These findings identify a critical protective role of BCL‐XL in the adult kidney and inform on the use of BCL‐XL inhibitors in combination with DNA damage‐inducing drugs for cancer therapy. Encouragingly, the combination of DNA damage‐inducing anti‐cancer therapy plus a BCL‐XL inhibitor could be tolerated in mice, at least when applied sequentially. 相似文献
122.
ORSOLYA SZOKOLÓCZI RICHÁRD SCHWAB ISTVÁN PETÁK LÁSZLÓ ÖRFI ÁKOS PAP ALEX N. EBERLE 《Journal of receptor and signal transduction research》2013,33(4-6):217-235
TT-232 is a structural analogue of somatostatin exhibiting strong and selective growth-inhibitory effects, inhibition of neurogenic inflammation, as well as general anti-inflammatory and analgesic potential without the wide-ranging endocrine side effects of the parent hormone and its “traditional” analogues. The anti-inflammatory action of TT-232 is mediated through the SSTR4 receptor, and its antitumor activity is mediated through the SSTR1 receptor and by the tumor-specific isoform of pyruvate kinase. Its mechanism of action is in line with a new era of molecular medicine called signal transduction therapy, where “false” intracellular or intercellular communication is inhibited or corrected without interfering with basic cell functions and machinery. TT232 has passed phase I clinical trials without toxicity and significant side effects, and phase II studies are running for oncological and anti-inflammatory indications, respectively. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic, and neurogenic inflammation-inhibiting activity can be achieved. 相似文献
123.
124.
125.
Background
A logical model of the known metabolic processes in S. cerevisiae was constructed from iFF708, an existing Flux Balance Analysis (FBA) model, and augmented with information from the KEGG online pathway database. The use of predicate logic as the knowledge representation for modelling enables an explicit representation of the structure of the metabolic network, and enables logical inference techniques to be used for model identification/improvement. 相似文献126.